Goodwin Technology and Life Sciences partner David Mardle shares what he sees as the biggest challenges facing life science SMEs at the moment, current and future investor behavior in the financing and M&A environment, and the new digital norm and legal processes companies must consider during this unprecedented time. Read the Q&A in LSX here.